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Despite the success of imatinib mesylate (IM) in the early
chronic phase of chronic myeloid leukemia (CML), patients are
resistant to IM and other kinase inhibitors in the later stages of
CML. Our ﬁndings indicate that inhibition of Janus kinase 2
(Jak2) in Bcr–Ablþ cells overcomes IM resistance although the
precise mechanism of Jak2 action is unknown. Knocking down
Jak2 in Bcr–Ablþ cells reduced levels of the Bcr–Abl protein
and also the phosphorylation of Tyr177 of Bcr–Abl, and Jak2
overexpression rescued these knockdown effects. Treatment of
Bcr–Ablþ cells with Jak2 inhibitors for 4–6h but not with IM
also reduced Bcr–Abl protein and pTyr177 levels. In vitro kinase
experiments performed with recombinant Jak2 showed that
Jak2 readily phosphorylated Tyr177 of Bcr–Abl (a Jak2
consensus site, YvnV) whereas c-Abl did not. Importantly,
Jak2 inhibition decreased pTyr177 Bcr–Abl in immune com-
plexes but did not reduce levels of Bcr–Abl, suggesting that the
reduction of Bcr–Abl by Jak2 inhibition is a separate event from
phosphorylation of Tyr177. Jak2 inhibition by chemical inhibi-
tors (TG101209/WP1193) and Jak2 knockdown diminished the
activation of Ras, PI-3 kinase pathways and reduced levels of
pTyrSTAT5. These ﬁndings suggest that Bcr–Abl stability and
oncogenic signaling in CML cells are under the control of Jak2.
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Introduction
Our previous experiments suggest that Janus kinase 2 (Jak2) has
an important role in Bcr–Ablþ cells, and that Bcr–Abl
expression leads to activation of Jak2.
1–3 Bcr–Abl is known to
drive the Grb2-Ras-Raf-Mek1/2 Erk pathway and the PI-3 kinase
pathway involving Gab2,
4–6 the Jak2-STAT3 pathway
7,8 and
the Bcr–Abl-STAT5 pathway.
9,10 Phosphorylation of Tyr 177
Bcr–Abl is a critical event required for development of chronic
myeloid leukemia (CML), as the Y177F mutant of Bcr–Abl
diminishes CML disease.
4,11,12 pTyr177 binds Grb2 leading to
Grb2–SOS complex formation and activation of the Ras path-
way. Continuous treatment with IM induces IM resistance
because of a number of events including mutations in the
tyrosine kinase domain (for example, T315I),
13 ampliﬁcation of
the Bcr–Abl gene
14,15 and a Bcr–Abl independent mechanism
involving Lyn kinase (for example, K562-R cells).
16,17 All these
events lead to poor responses to IM therapy, allowing
progression of the disease. Jak2 activation in Bcr–Ablþ cells
appears not to involve phosphorylation of Jak2 by the Bcr–Abl
tyrosine kinase but the interaction of Bcr–Abl with the IL-3
receptor chains, speciﬁcally the b-chain of the receptor.
18,19 The
Bcr–Abl/Jak2 signaling pathway appears to be housed in a high-
molecular weight structure called the Bcr–Abl network com-
plex.
20–22 Importantly, Jak2 kinase inhibition overcomes IM
resistance by inducing apoptosis in IM-resistant cell lines
(including T315I cells) and also cells from CML patients at the
blast crisis stage.
20,21
Residual CML disease appears to involve primitive progenitor
cells, which have been shown to be present in niches in the
bone marrow.
23,24 These cells are considered quiescent and not
Bcr–Abl dependent.
25–27 These ﬁndings require a search for new
therapeutic targets and compounds to eradicate these tyrosine
kinase inhibitors-resistant cells from the bone marrow niche.
Jak2 is an important signaling component in hematopoietic
cells, as it transmits signals generated by interaction of cytokines
such as IL-3 with the IL-3 receptor. The a- and b-chains of the
IL-3 receptor are part of a large dodecamer structure in which
two Jak2 molecules are bound to the b-chain in close proximity
to each other.
28 Jak2, as a result of interaction of IL-3 with the
IL-3 receptor, becomes activated by autophosphorylation at Tyr
1007.
28,29 Studies by Huang et al.
30 suggest that IL-3 signaling
driven by activated Jak2 is enhanced by Jak1 interaction with
Jak2. Our new ﬁndings indicate that Jak2 controls Bcr–Abl
signaling in CML cells, as either Jak2 knockdown or Jak2
inhibition drastically reduced the levels of Bcr–Abl and the
phosphorylation of Tyr 177 within Bcr–Abl causing reduction of
oncogenic signaling.
Materials and methods
See Supplementary Material and Methods.
Results
Jak2 knockdown reduced levels of Bcr–Abl protein and
Tyr 177 phosphorylated form of Bcr–Abl in mouse
hematopoietic and CML cell lines
Our ﬁndings with Bcr–Ablþ cell lines including cells expres-
sing imatinib mesylate (IM)-resistant forms of Bcr–Abl indicate
that Jak2 is a critical player in CML.
20,22 We began exploring the
mechanisms behind this critical role of Jak2 in CML. We found
that Jak2 controls Bcr–Abl protein levels, as Jak2 knockdown
causes a rapid disappearance of Bcr–Abl (Figure 1). We used a
speciﬁc mouse form of Jak2 small interfering RNA to knock-
down Jak2 in Bcr–Ablþ 32D mouse myeloid cells (Figure 1a).
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www.nature.com/leuJak2 knockdown dramatically reduced levels of the pTyr
Bcr–Abl protein. To offset the possible nonspeciﬁc effects of
Jak2 knockdown, we rescued Jak2 knockdown by transducing
Jak2 cDNA into cells at the time of Jak2 knockdown. The
rescued cells had restored levels of pTyr Bcr–Abl in cells
corresponding to the restored expression of Jak2, suggesting that
Jak2 controls the expression of Bcr–Abl.
We also used an inducible form of speciﬁc human Jak2 short
hairpin RNA to knockdown Jak2 in three CML cell lines, namely
BV173, KBM-7 and K562-R. Levels of Jak2 were reduced and
also Bcr–Abl protein levels were drastically reduced following
Jak2 knockdown in K562-R cells (Figures 1b and c). Reversal of
Jak2 knockdown (removal of the inducer doxicycline) restored
the expression of the Bcr–Abl protein (Figure 1d).
In Jak2 knockdown experiments, levels of Tyr177 phosphory-
lation within Bcr–Abl were also strongly inhibited as expected
as Bcr–Abl had also disappeared. Importantly, rescue experi-
ments partially restored levels of pTyr177 (Figures 1a–d). Similar
results were observed by Jak2 knockdown in CML cell lines
BV173 and KBM7 (Supplementary Figure 1a–c).
Jak2 phosphorylated the tyrosine 177 Bcr sequence
found in Bcr–Abl
An analysis of the Bcr–Abl sequence revealed various tyrosine
residues that are Jak2 consensus phosphorylating sites (YxxV/L/I)
(Supplementary Table 1).
31 We observed that tyrosine 177
within Bcr–Abl (YxxV) ﬁts the consensus Jak2 phosphorylation
motif. To test whether Jak2 would phosphorylate Tyr177, we
made a Bcr peptide that contains sequences surrounding the
tyrosine 177 sequence of Bcr–Abl, and used that peptide as
a target for Jak2 (Figures 2a–c). Puriﬁed recombinant Jak2
(JH1 domain) readily phosphorylated this peptide and this phos-
phorylation was strongly inhibited by the selective Jak2 inhibitor
TG101209 (TG) but not by IM (Figures 2a and b). We note that
TG is a potent inhibitor of Jak2’s ability to phosphorylate Tyr
177 in kinase assays with an BIC 50 of less than 0.01mM
(reported to be 6nM)
35 (Supplementary Figure 1d).
Jak2 immune complexes isolated from Bcr–Ablþ 32D cells
also phosphorylated the Tyr 177 Bcr peptide and phosphory-
lation was inhibited by TG but not by IM (Figure 2a). These Jak2
immune complexes contain Bcr–Abl, Jak2 and HSP90 and other
signaling members such as Akt and STAT3.
20,21 Thus, although
Bcr–Abl is present in the Jak2 immune complex (see Supple-
mentary Figure 1a, b), it does not phosphorylate Tyr 177 as IM
does not inhibit tyrosine phosphorylation of the peptide
(Figure 2a). We note that puriﬁed near full-length recombinant
c-Abl kinase only poorly phosphorylated the Tyr 177 site in the
Bcr peptide (Figure 2c).
Jak2 inhibition of phosphorylation of Tyr177 is a
separate event from disappearance of Bcr–Abl
To determine whether the disappearance of Bcr–Abl could be
separated from the inhibition of Tyr 177 phosphorylation, we
performed kinase assays with immune complexes harvested
from Bcr–Ablþ 32D cells with anti-Jak2 antibodies, and
determined whether Jak2 inhibition would decrease levels
of pTyr177 and whether levels of Bcr–Abl in the immune
complexes would also be reduced by Jak2 inhibition. The
Bcr–Abl protein was not decreased in these immune complexes
by Jak2 inhibition but importantly levels of pTyr177 were
strongly decreased (Figures 2d, e). Similarly, levels of pTyr
Bcr–Abl were not reduced by treatment of the kinase reaction
mixture with 5 and 10mM TG (Figure 2d). Importantly, Jak2 and
Bcr–Abl coprecipitated in immune complexes (Supplementary
Figure 1e and f). These results indicate that the events leading
to the decrease of Bcr–Abl occurred within intact cells but not
in immune complexes from these same cells and, more
importantly, the inhibition of phosphorylation of Tyr177 by
TG can readily occur in these subcellular fractions under
conditions wherein Bcr–Abl levels were stable. Importantly, we
found that Jak2 inhibition caused only background levels of
apoptosis during the ﬁrst 4h of treatment wherein Bcr–Abl levels
were strongly reduced (Supplementary Figure 5c).
Jak2 inhibitor TG101209 rapidly decreased the levels of
pTyr177 Bcr–Abl
We tested the effects of Jak2 inhibition in various Bcr–Ablþ cell
lines and CML cell lines. Jak2 inhibition reduced levels of active
Jak2 in a dose-dependent manner.
22 The 50% point of Jak2
inhibition as measured by pTyr1007 phosphorylation was
estimated to be 5mM as estimated by quantitation of the intensity
values (Figure 3a). Similarly, the level of Bcr–Abl pTyr177 was
inhibited in a dose-dependent manner and the 50% inhibitory
point was estimated to be 5mM. The 50% inhibitory point for
Bcr–Abl reduction was estimated to be B7.5mM. Interestingly,
the selective Jak2 inhibitor TG rapidly decreased levels of
phosphorylation of Tyr177 of Bcr–Abl but also decreased levels
of Bcr–Abl during this time period (Figure 3b). The CML cell line
K562-R showed rapid loss of pTyr177 Bcr–Abl and the
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Figure 1 Knockdown of Jak2 strongly reduced levels of the Bcr–Abl protein and pTyr 177 of Bcr–Abl in Bcr–Ablþ cells and CML cell lines.
(a) Knockdown of Jak2 and rescue of Jak2 expression in Bcr–Ablþ 32D cells (32Dp210) using Jak2-speciﬁc small interfering RNA. 32Dp210
contains a b3a2 form of Bcr–Abl expressed in mouse myeloid 32D cells. (b) Knockdown of Jak2 in K562-R CML cell line by an inducible
Jak2-speciﬁc short hairpin RNA. Jak2 knockdown was initiated by addition of doxicycline (2mg/ml) for 3 days. (c) Non-targeted short hairpin
RNA has no effects on Jak2 expression and Bcr–Abl expression. (d) Reversal of Jak2 knockdown restores levels of pTyr177 and the Bcr–Abl protein.
After a 3-day induction, doxicycline was withdrawn from the culture for 6 days. Western blotting with the appropriate antibodies was performed in
these studies.
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LeukemiaBcr–Abl protein after 3h (Figure 3c), as did KBM7 CML cells
(Supplementary Figure 1g). Reductions of pTyr177 Bcr–Abl and
Bcr–Abl were seen in CML cell line K562 (Supplementary Figure
1h). Cells from a blast crisis CML patient treated with TG101209
also had a reduction of pTyr177 Bcr–Abl and Bcr–Abl protein
(Figure 3d). We also showed that Jak2 inhibition rapidly reduced
the levels of total pTyr proteins (Figure 3e).
The Jak2 consensus sites include YxxV/L/I
31 and there are a
number of these Jak2 consensus sites in Bcr–Abl (Supplementary
Table 1). We wondered whether YxxF would also be a site that
is phosphorylated by Jak2, as F-like V/L/I is a hydrophobic
amino acid. There are three such sites in Bcr–Abl including Tyr
360. We had made a mouse monoclonal antibody against the
pTyr360 sequence of Bcr. This sequence-speciﬁc pTyr mono-
clonal antibody detected a signal in Bcr–Abl, and Jak2 inhibition
by a new Jak2 inhibitor WP1193 (see below) dramatically
reduced the level of pTyr360 Bcr–Abl within 60min (Supple-
mentary Figure 2a), suggesting that Jak2 also phosphorylates
Tyr360 of Bcr–Abl.
pTyr177 within P160 BCR is also rapidly reduced by
Jak2 inhibition
Similar to Bcr–Abl, phosphorylation of Tyr177 within P160 BCR
was also rapidly reduced by treatment with 10mM TG (Supple-
mentary Figure 1i). As Bcr is believed to form heterotetramers
with Bcr–Abl, these results suggest that Jak2 would phosphory-
late Tyr177 within Bcr–Abl and Bcr in these heterotetramers. It is
unknown whether phosphorylation of Bcr on Tyr177 would
contribute to activation of Ras and PI-3 kinase pathways in
CML cells.
CML 34þ cells respond to Jak2 inhibition by reduction
of pTyr177 Bcr–Abl and Bcr–Abl
Cells were harvested from the peripheral blood of a CML blast
crisis patient, having 98% blasts. After CD34 selection, sufﬁcient
cells were available for western blotting (3 million cells). Flow
cytometry results indicated that 87% of the cells bound to the
CD34 beads were CD34þ (results not shown). Western blotting
revealed that Jak2 inhibition by TG reduced levels of pTyr177
and Bcr–Abl in CD34þ cells (Figure 3f). We note that
CD34þcells from this patient were resistant to IM but sensitive
to TG (Supplementary Figure 4a).
Cord blood CD34þ cells showed loss of Bcr–Abl and
pTyr177 Bcr–Abl caused by Jak2 inhibition
We examined the effects of Jak2 inhibition in CD34þ cord
blood cells transduced with BCR–ABL.
12 The cells were treated
for 6h with 2.5 and 10mM TG. pTyr177 Bcr–Abl and Bcr–Abl
were drastically reduced as was Jak2 and activated Jak2 (pTyr
1007) following treatment of CD34þ cells with TG (Figure 3g).
These results with CD34þ cord blood cells, which were
recently transduced with Bcr–Abl, would be consistent with Jak2
inhibiting early progenitor cells in CML patients.
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Figure 2 Jak2 phosphorylates Bcr–Abl on Tyr177. (a) Jak2 inhibitor TG101209 (TG, TargeGen Inc., San Diego, CA, USA) but not IM inhibited
phosphorylation of a Bcr Tyr177 peptide (custom synthesized by Bachem Co., Torrance, CA, USA) in Jak2 immune complexes from the cell lysates
of 32Dp210 cells immunoprecipitated with anti-Jak2 antibody coupled to agarose beads. The target peptide has the Bcr sequence H-Ala-Glu-Lys-
Pro-Phe-Tyr(177)-Val-Asn-Val-Glu-Phe-His-His-Glu-(Lys-Lys-Lys). The bolded amino acids are the Grb2 binding site in Bcr–Abl (YVNV) and are
the Jak2 consensus phosphorylation site. The three Lys residues allow binding to Whatman 3mm ﬁlters. Anti-Jak2 immune complexes were
incubated in a kinase assay with g p32 ATP in the presence of various concentrations of either Jak2 inhibitor TG or IM. (b) Jak2 inhibition of
recombinant Jak2 (JH1 domain, 50ng; Invitrogen, Carlsbad, CA, USA) by TG but not IM inhibited phosphorylation of a Tyr177 Bcr peptide. The
Jak2 kinase assay with g p32 ATP was performed using recombinant Jak2 kinase (JH1 domain, GST-Jak2 aa808–1132 in presence of either Jak2
inhibitor TG or IM using the Bcr synthetic target peptide containing Tyr177 sequence. (c) Jak2 efﬁciently phosphorylates the Tyr177 Bcr whereas
c-Abl prefers to phosphorylate the YxxP sequence. Recombinant JH1 of Jak2 was used to phosphorylate either the Bcr Tyr177 peptide or the
Abltide peptide (BIOMOL International, Plymouth Meeting, PA, USA). (d) Jak2 inhibition reduced levels of pTyr177 Bcr–Abl in kinase assays
performed with anti-Jak2 immune complexes but did not reduce levels of Bcr–Abl. Mouse 32Dp210 cells were lysed and anti-Jak2 immune
complexes were harvested as described.
2 Lysates were western blotted with either pTyr 177 Bcr antibody or anti-Abl 8e9 antibody. (e) Jak2
inhibition reduced levels of pTyr 177 Bcr–Abl in kinase assays performed with anti-Abl p6D monoclonal antibody
2 but had no effect on levels of
the Bcr–Abl protein.
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LeukemiaInhibition of the Bcr–Abl kinase by IM had little effect
on the phosphorylation of Tyr177 of Bcr–Abl in
short-term experiments
Importantly, IM, a well-known Abl kinase inhibitor, did not
inhibit tyrosine phosphorylation of Tyr177 of Bcr–Abl for up to
3h within Bcr–Ablþ cells nor was the level of the Bcr–Abl
protein affected during 3-h treatment with IM (Figure 3h).
These results provide further evidence that Tyr177 of Bcr–Abl is
a site phosphorylated by Jak2 and does not result from a
Bcr–Abl autophosphorylation reaction. However, treatment of
Bcr–Ablþ cells with IM for longer times, as expected, drastically
decreased Bcr–Abl protein levels in a dose-dependent manner
(1–10mM, 16h, not shown).
Jak2 inhibition reduced activation of the Ras, PI-3
kinase and STAT5 pathways
We determined whether binding of Grb2 to Bcr–Abl was
similarly decreased by Jak2 inhibition. It is known that Grb2
binds to pTyr177 of Bcr–Abl and pTyr Shc; Shc also contains the
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Figure 3 Jak2 inhibition by TG101209 induced dephosphorylation of Bcr–Abl Tyr177 and reduction of Bcr–Abl. (a) Bcr–Abl pTyr177 and
Bcr–Abl levels were reduced in 32Dp210 cells treated with indicated doses of Jak2 inhibitor TG for 16h. Anti-Abl immunoprecipitates (IP) (P6D
monoclonal antibody, custom made) were probed by western blotting (WB) with sequence-speciﬁc Bcr pTyr177 antibody (Novus Biologicals,
Littleton, CO, USA) and anti-Abl 8E9. Anti-actin (Sigma Chem Co., St Louis, MO, USA) blots were performed on the supernatant before IP as a
loading control. IQ represents normalized intensity performed by estimating the band intensity and dividing that by the intensity of the actin band.
(b) Jak2 inhibition by TG rapidly reduced pTyr177 Bcr–Abl but had little effect on the level of Bcr–Abl levels. 32Dp210 cells were treated with the
10mM TG for various times up to 2h and assayed by western blotting. (c) Jak2 inhibition by TG in CML cell line K562-R reduced levels of Bcr–Abl
pTyr177 and Bcr–Abl protein. (d) Cells from a blast crisis (78% blasts) CML patient showed reduced levels of pTyr177 Bcr–Abl and Bcr–Abl by Jak2
inhibition. Monocytes were isolated by Histopaque (Sigma Chem Co.) separation and grown for 24h in culture medium without growth factors
before TG treatment. (e) Jak2 inhibition by TG rapidly reduced levels of pTyr-containing proteins. Lysates were blotted with 4G10 anti-pTyr
antibody. (f) CD34þ progenitor cells from a blast crisis CML patient (98% blasts) showed rapid reduction of pTyr177 Bcr–Abl and Bcr–Abl upon
treatment with TG for up to 2h. After isolation of monocytes as in panel d, cells were then fractionated on CD34 antibody magnetic beads. An
aliquot assayed by ﬂow cytometry showed that the sample was 87%þ for CD34þ cells. The CD34þ cells were treated with 10mM TG for up to
2h in cell culture. (g) Jak2 inhibition by TG reduced levels of pTyr177 Bcr–Abl, Bcr–Abl, Jak2, pTyr1007 Jak2 in human cord blood CD34þ
progenitor cells transduced with BCR–ABL as described.
12 TG treatment was done for 6h. (h) Treatment of 32Dp210 cells with IM had little effect
on levels of pTyr177 Bcr–Abl and Bcr–Abl protein levels over a 3-h period.
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LeukemiaGrb2-binding sequence YvnV sequence. Shc associates with
Bcr–Abl and like pTyr177, drives the Ras and PI-3 kinase
pathways. Grb2 levels in the Bcr–Abl immunocomplex was
reduced by B60% within 120min of TG treatment compared
with the control (Figure 4a). Jak2 inhibition by TG decreased
levels of RAS GTP within 60min in 32Dp210 cells (Figures 4b
and c), which is consistent with the observed decrease in Grb2
binding to Bcr–Abl. We also determined whether Jak2 inhibition
decreased PI-3 kinase activation. It is known that pTyr177 binds
Grb2 which in turn binds Gab2.
6 Our previous studies
20
indicate that Jak2 activation leads to phosphorylation of
Tyr 452 of Gab2, which is involved in binding to the regulatory
subunit of the PI-3 kinase leading to its activation.
6 In our
current studies, pTyr 452 Gab2 was rapidly decreased in
Bcr–Ablþ cells after treatment with TG (Figure 4d). We note
that PI-3 kinase activation as measured by a commercial kit
was also decreased within 60–120min of Jak2 inhibition (not
shown). These results indicate that Jak2 inhibition rapidly
inhibited both Ras and PI-3 kinase activation.
We determined whether STAT5 activation would also be
downregulated by this more potent Jak2 inhibitor. Jak2
inhibition rapidly decreased pTyr levels of STAT5 (Figure 4e),
which is consistent with downregulation of STAT5 transcrip-
tional activity. It remains to be determined whether inactivation
of Bcr–Abl by Jak2 interferes with Bcr–Abl’s ability to activate
STAT5.
Jak2 knockdown reduced levels of tyrosine
phosphorylation of Shc and Gab2
The reduction of Grb2 binding to Bcr–Abl and the resultant
decrease in Ras activation prompted an examination of Jak2
effects on phosphorylation of Shc. It is known that pTyr Shc (at
the YvnV sequence) also binds Grb2 leading to Ras activation.
Knockdown of Jak2 strongly decreased levels of pTyr Shc in
CML cell line K562-R (Figure 4f) and BV173 cells (not shown).
Thus, Jak2 inhibition not only reduced levels of Grb2 binding
to Bcr–Abl, but Jak2 knockdown also reduced the alternate
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Figure 4 Jak2 inhibition by TG reduced activation of the Ras pathway and PI-3 kinase pathways. (a) Jak2 inhibition of 32Dp210 cells reduced
binding of Grb2 to anti-Abl immunoprecipitates. (b) Jak2 inhibition by TG reduced levels of Ras GTP in 32Dp210 cells. These assays were
performed with a commercial kit as described by the manufacturer. It involves IP/westerns with their RAS GTP antibody. The kit allows for
generation of internal positive and negative controls; the third control is untreated Bcr–Ablþ cells. (c) Quantitation of RAS GTP levels following
treatment of 32Dp210 cells with 10mM TG. The intensity values of the RAS GTP bands were divided by the intensity of the actin band. (d) Jak2
inhibition by TG rapidly reduced levels of pTyr (452 YxxM) Gab2 in 32Dp210 cells. pTyr 452 is believed to bind to regulatory subunit of the PI-3
kinase, which is required for activation of PI-3 kinase. (e) Jak2 inhibition by TG rapidly decreased tyrosine phosphorylation of STAT5 (residue 694).
(f) Knockdown of Jak2 reduced pathways related to the Bcr–Abl/Jak2 pathway in CML cell line K562-R. Jak2-speciﬁc short hairpin RNA was
induced by treatment of cells with doxicycline as in Figure 1. The lysate was western blotted with the antibodies listed.
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Leukemiapathway for activating Ras, namely the tyrosine phosphorylation
of Shc. Both of the effects of Jak2 inhibition would lead to
reduced levels of Ras activation.
Jak2 knockdown also reduced levels of pTyr Gab2, which
binds to Grb2,
6 thereby reducing the activation of the PI-3
kinase pathway in K562-R cells. The levels of pMEK1 and 2,
pSer 9 of GSK3 and pTyr STAT5 were also reduced by Jak2
knockdown (Figure 4f) in BV173 cells (not shown). Jak2 controls
the Gab2/PI-3 kinase, Akt and GSK3 through its ability to induce
phosphorylation of Gab2
20 and would control Ras acti-
vation and downstream MEK activation by Jak2’s ability to
phosphorylate Tyr177 of Bcr–Abl and Tyr 239/240 of Shc. We
note that Jak2 knockdown did not decrease either Lyn kinase or
total Grb2 levels (Figure 4f). Our ﬁndings indicate that Lyn
kinase is not part of the Bcr–Abl/Jak2/HSP90 network com-
plex.
22 Thus, prolonged Jak2 inhibition would seriously depress
levels of activated Ras and PI-3 kinase activation in Bcr–Ablþ
leukemia cells.
A new pan Jak kinase inhibitor, inhibits Jak2 effects on
Bcr–Abl and Tyr177 phosphorylation
We tested the effects of a more potent analog of the Jak2
inhibitor AG490 (WP1193, Figure 5a) for its ability to reduce
Bcr–Abl and to inhibit phosphorylation of Tyr177 of Bcr–Abl.
WP1193 inhibited the phosphorylation of Tyr177 housed within
the Bcr peptide with 50% inhibition point of o2.5mM
(Figure 5b). Like AG490, WP1193 inhibited tyrosine phosphory-
lation of Jak2 in cells (Figure 5c) and also inhibited tyrosine
phosphorylation of Jak1 and Jak3 (not shown); WP1193 also
inhibited the autophosphorylation of Jak2 in vitro (Supplemen-
tary Figure 2b). It has been reported that Jak1 kinase interacts
with Jak2 leading to the strengthening of the downstream effects
of cytokine signaling through Jak2.
30 WP1193 rapidly reduced
levels of Bcr–Abl and pTyr177 Bcr–Abl within several Bcr–
Ablþ cell lines including T315I cells and cells from blast crisis
CML patients (Figures 5c–e). WP1193 appeared to be more
potent than TG (compare Figures 5c–e with Figures 3b–d).
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Figure 5 A new Jak2 inhibitor WP1193 rapidly reduced levels of pTyr177 Bcr–Abl, Bcr–Abl protein and levels of pTyr Bcr–Abl in 32Dp210 cells.
(a) Structure of WP1193 and AG490. AG490 is a known Jak kinase inhibitor. (b) Jak2 inhibitor WP1193 inhibits the ability of recombinant Jak2
(JH1-JH2) to phosphorylate Tyr177 Bcr peptide. The same methods were used as described in Figure 2. (c) Top panel: Jak2 inhibitor WP1193
rapidly inhibited phosphorylation of Tyr177 of Bcr–Abl and reduced levels of Bcr–Abl in 32Dp210 cells. 32Dp210 cells were lysed and
immunoprecipitated with anti-Abl p6D monoclonal antibody as described in Figure 2a. Bottom panel: 32Dp210 cells were treated for up to 1h
with 10mM WP1193, lysates were made and immunoprecipitated with anti-Jak2 antibody. Western blots were probed with anti-pTyr 4G10.
(d) Jak2 inhibition by WP1193 causes rapid reduction of pTyr177 Bcr–Abl and the Bcr–Abl protein in BaF3 cells expressing IM-resistant form of
Bcr–Abl containing the T315I mutation. (e) Jak2 inhibition by WP1193 caused rapid reduction of pTyr177 Bcr–Abl in cells from a blast crisis CML
patient. Monocytes from patients were isolated by Histopaque (Sigma Chem Co.,) separation and grown for 24h in culture medium without growth
factors before WP1193 treatment. (f) The level of the Y177F Bcr–Abl mutant is decreased in amount similar to wild-type Bcr–Abl as a result of Jak2
inhibition. 32D cells were transfected with either Y177F BCR–ABL mutant or wild-type BCR–ABL. Cells were allowed to grow in the absence of
IL-3 for about 3 weeks. Cells were treated with 10mM WP1193 for 30min. Lysates were analyzed by western blotting with anti-Abl 8E9, anti-Tyr
177 Bcr, anti-Jak2 pTyr 1007/8 and anti-Jak2 antibodies. (g) Levels of Grb2 were rapidly reduced in anti-Abl immune complexes containing
Bcr–Abl. (h) Levels of Ras GTP were rapidly reduced in 32Dp210 cells treated with Jak2 inhibitor WP1193. Experiments were performed as in
Figure 4b. (i) Quantitation of RasGTP levels in 32Dp210 cells treated with Jak2 inhibitor WP1193. Quantitation was done as shown in Figure 4c.
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Tyr177, and Bcr–Abl reduction for WP1193 was between 2.0 and
3.0mM in whole cells, respectively (Supplementary Figure 2h).
Overall, the pan Jak inhibitor, although much less potent in Jak2
kinase assays than TG101209 (estimated 50% inhibition point of
about 2mM f o rW P 1 1 9 3c o m p a r e dw i t h0 . 0 1mM for TG (compare
Figure 5b with Supplementary Figure 1d), WP1193 was similar if
not more potent at reducing levels of Bcr–Abl and pTyr177
compared with TG101209 (compare inhibition by WP1193 and
TG101209 in Figures 5c–e and Figures 3b–d, respectively).
Like TG, WP1193 was able to reduce binding of Grb2 to
Bcr–Abl complexes while reducing levels of pTyr177 Bcr–Abl
(Figure 5g). WP1193 rapidly reduced RAS GTP levels (Figures
5h and i) and pTyr Gab2, and STAT5 levels (Supplementary
Figure 2c, e, respectively). WP1193 was a potent inhibitor of the
Jak2 kinase in a test tube kinase assay (Supplementary Figure 2b)
but did not inhibit the Bcr–Abl kinase (Supplementary Figure 2f)
whereas IM, as expected, inhibited the Bcr–Abl kinase
(Supplementary Figure 2g).
Tyr177 Y to F mutant behaves as wild-type Bcr–Abl with
respect to Jak2 inhibition
We compared the disappearance of Y177F Bcr–Abl mutant with
wild-type Bcr–Abl in 32D cells transduced with either wild-type
or mutant BCR–ABL. The results indicate that Jak2 inhibition
by WP1193 for 30min caused similar levels of Bcr–Abl
disappearance in both mutant and wild-type forms (Figure 5f).
Moreover, as expected, Tyr177 phosphorylation was not
detected in the Y177F mutant (Figure 5f). These results support
the concept that Tyr177 is just one of possibly several Jak2
phosphorylation sites (Tyr360 being another, see Supplementary
Table 1), and that phosphorylation of these sites is necessary to
maintain Bcr–Abl in a functional state.
Jak2 inhibition reduced tumorgenicity in mouse models
As WP1193 was a more potent Jak2 inhibitor than TG, we tested
the effects of WP1193 on the growth of tumors induced by
IM-resistant K562-R cells. K562-R cells
16 contain activated Lyn
kinase, which maintains the leukemic state of the K562-R cells
despite the presence of IM. Therefore, we tested the inhibitory
effects of WP1193 on the growth of solid tumors induced by
K562-R in a nude mouse model. Solid tumors were allowed
to form for 12 days following injection of K562-R cells, and
treatment with WP1193 was initiated at 12 days through
day 22 (Figure 6a). The volume of solid tumors was determined
following injection of WP1193 at 30mg/kg of mouse body
weight every 48h. Solid tumor growth was signiﬁcantly reduced
(P-value of 0.007) over this time period (Figures 6a and b).
Injection of these mice with WP1193 by intraperitoneal (i.p.)
had little effect on the weights of spleen and liver tissue
(Supplementary Figure 3c, d).
We next compared the effects of WP1193 at 30mg/kg (i.p.) on
the oncogenic effects of IM-resistant T315I Bcr–Ablþ 32D cells
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Figure 6 Jak2 inhibition by WP1193 inhibited solid tumor formation caused by IM-resistant K562 cells and strongly reduced tumors effects
caused by Bcr–Abl T315I. (a) WP1193 inhibits solid tumor formation in nude mice injected subcutaneously (s.c) with 5 million K562-R cells. Five
mice were injected with WP1193 (30mg/kg) every 48h beginning 12 days after injection of cells through 22 days. (b) Quantitation of tumor weight
from ﬁve mice. (c and d) WP1193 reduced the weight of liver and spleens (right spleen in ﬁgure) in leukemic injected with Bcr–Abl T315Iþ BaF3
cells (B2.5 million cells). Mice were injected every 48h by the i.p. route with WP1193 beginning 1 day after cell inoculation and killed 1 day after
the seventh injection. (e) Reduction of spleen weight by WP1193 in mice injected with Bcr–Abl T315I BaF3 cells. (f) Model describing how Jak2
regulates signaling in CML cells.
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Leukemiainjected intravenous (i.v.) in the nude mouse model. The mice
developed large intestinal tumors over a 2-week period
(Supplementary Figure 3a), which were largely prevented by
WP1193 treatment (Supplementary Figure 3b, Figures 6c–e).
Spleen and liver weights were reduced (Figures 6c–e), and
spleens were enlarged in the diseased mice compared with
WP1193-treated mice (Figures 6d and e).
Importantly, spleens and livers of mice not injected with
leukemia cells were not signiﬁcantly affected in weight by
injection of WP1193 over a 3-week period (Figures 6c and e); all
of these drug-treated mice survived and showed little evidence
of acute toxicity as the mice appeared healthy.
Jak2 inhibition induced apoptosis in CD34þ cells from
blast crisis IM-resistant CML patients and cells from
chronic phase IM-resistant CML patients
We harvested CD34þ progenitor cells from a patient with blast
crisis CML. Fractionated cells were treated with either IM or TG.
After 48h, cells were analyzed by annexin/PI ﬂow cytometry.
TG at 5mM concentration induced 80% apoptosis whereas IM at
5–10mM concentration had little apoptotic-inducing activity
(Supplementary Figure 4a); (the same patient cells used in
Figure 3f). All of our previous studies had shown that Jak2
inhibition
20,21 induced apoptosis in cells from blast crisis CML
patients. We also examined cells from chronic phase CML
patients who were resistant to IM. Treatment of the chronic
phase cells with 2.5 10mM TG induced high levels of apoptosis
whereas IM treatment had little effect in these samples
(Supplementary Figure 4b–d). Cells from one chronic phase
patient were partially sensitive to IM but these cells were almost
completely killed by 5mM TG (Supplementary Figure 4b). Cells
from an accelerated phase CML patient, although resistant to IM,
were quite sensitive to Jak2 inhibition with either TG or
WP1193 (Supplementary Figure 4e). We note that BaF3 cells
expressing the T315I form of Bcr–Abl, although resistant to IM
as expected, were quite sensitive to TG at 5mM and above
(Supplementary Figure 4f).
Discussion
Our previous ﬁndings indicate that Jak2 is a critical signaling
molecule in CML.
20,21 The most pertinent of these ﬁndings
is that AG490, an inhibitor of Jak2, induced apoptosis in
IM-resistant Bcr–Ablþ cell lines including BaF3 cells expressing
the gate keeper IM-resistant mutant T315I
13 of Bcr–Abl.
20 To
pursue the effects of Jak2 inhibition further, we performed
experiments with Jak2-speciﬁc short hairpin RNAs in three
different CML cell lines and in 32Dp210 cells expressing Jak2-
speciﬁc small interfering RNAs. We made a surprising ﬁnding
that Jak2 knockdown caused a disappearance of Bcr–Abl from
the lysate. The mechanism of this Jak2 inhibition effect on
Bcr–Abl is unknown, but is under study.
Another effect of Jak2 inhibition in Bcr–Ablþ cells is the
reduction of phosphorylation of Tyr177 of Bcr–Abl. Recombi-
nant Jak2 (JH1) readily phosphorylated Tyr177 in a Bcr peptide,
and this phosphorylation was strongly inhibited by a selective
Jak2 inhibitor TG101209 but not by IM. Tyr177 phosphorylation
in this system was also inhibited by a new Jak2 inhibitor,
WP1193. Although Jak2 inhibition leads to reduction of pTyr
177 Bcr–Abl in Bcr–Ablþ cell lines and in cells from blast crisis
patients, this whole-cell effect is less clear as Jak2 inhibition also
decreased levels of the Bcr–Abl protein. However, in vitro
immune complex kinase assays showed that Jak2 inhibition did
not reduce levels of Bcr–Abl in immune complexes but strongly
inhibited phosphorylation of Tyr177. Thus, our hypothesis is that
Jak2 inhibition decreases phosphorylation of Tyr177 within
Bcr–Abl and possibly other Tyr residues within Bcr–Abl. In this
regard, there are eight consensus Jak2 phosphorylation sites
(YxxV/L/I) within the Bcr portion of Bcr–Abl (b3a2) of which
Tyr177 is one such site (Supplementary Table 1). We propose
that decreases in Tyr phosphorylation renders Bcr–Abl insoluble
in the non-ionic detergent extraction buffer normally used to
solubilize Bcr–Abl. This insolubility may be caused by the
destruction of the network structure that maintains leukemic
signaling in Bcr–Ablþ cells.
22 We have shown that another
Jak2 inhibitor, which also inhibits the Bcr–Abl kinase, also
causes rapid disappearance of Bcr–Abl. Importantly, this dual
kinase inhibitor (ON 044580) causes the disruption of the
HSP90 structure that houses Bcr–Abl and Jak2 within and other
signaling components of the Bcr–Abl/Jak2 pathway.
22
Of interest, CD34þ cells from CML blast crisis patients and
from CD34þ cord blood cells transduced with BCR–ABL also
showed reduction of Bcr–Abl and pTyr177 Bcr–Abl levels upon
Jak2 inhibition, indicating that the dominant effects of Jak2
inhibition also occur in early progenitor cells.
Downregulation of Ras activation and the initial stage of PI-3
kinase activation (reduction of pTyr Gab2), and the inhibition of
Tyr phosphorylation of STAT5 following Jak2 inhibition suggests
that the Jak2 tyrosine kinase is the critical tyrosine kinase that
drives major signaling pathways in the leukemic cell. These
results partially explain why Jak2 inhibition can overcome IM
resistance (Supplementary Figure 4, 5).
20,21 What remains is
whether the tyrosine kinase function of Bcr–Abl is needed to
activate the Jak2 kinase. Our studies indicate that Bcr–Abl alone
does not lead to Jak2 activation, as addition of the IL-3 receptor
is required.
18
It is of interest that the Jak2 kinase seems to be involved in
phosphorylation of Tyr 360 of Bcr–Abl. Our studies with Bcr
serine kinase indicate that Tyr 360 is a critical regulator of Bcr
serine/threonine kinase activity,
32,33 and that phosphorylation
of Tyr360 of Bcr downregulates its serine/threonine kinase
activity.
32,33 Bcr resembles kinases such as pyruvate kinase,
which is known to require a free tyrosine residue to maintain its
kinase activity.
34 The fact that Y177F mutant of Bcr–Abl is
similar to wild-type Bcr–Abl in response to Jak2 inhibition,
suggests that Tyr177 is one of several possible Jak2 phosphory-
lation sites (including Tyr360) in Bcr–Abl necessary to maintain
functional Bcr–Abl levels (Figure 5f).
Transmission of downstream signals induced by IL-3 may be
enhanced by Jak1 interaction with Jak2.
30 In this regard, we
found that a putative pan Jak kinase inhibitor (WP1193)
appeared to be more potent in reducing levels of Bcr–Abl and
reducing levels of pTyr177 in Bcr–Ablþ cells compared with
the selective Jak2 kinase inhibitor (TG101209).
35 We note that
WP1193, despite its considerably less in vitro potency for
phosphorylating Tyr177 in kinase assays compared with TG
(approximately 100-fold), still maintained similar or greater
potency to reduce Jak2 effects in intact cells expressing Bcr–Abl.
It is possible that WP1193’s greater in vivo potency may be
because of its ability to inhibit Jak1 as well Jak2 inside
Bcr–Ablþ cells, although other explanations are possible.
Because of the apparent increased overall potency of
WP1193 compared with TG101209, we chose to test WP1193
for its effects on inhibition of Bcr–Abl’s oncogenic effects in
mouse tumor models. The results indicate that WP1193 was
a potent inhibitor of solid tumor formation induced by CML
line K562-R and a strong inhibitor of oncogenic effects of
IM-resistant T315I in nude mice. Moreover, WP1193 had no
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Leukemiaobservable toxic effects on mice injected with WP1193 only
over a 2-week period.
Importantly, Jak2 inhibition was effective in apoptosis
induction in IM-resistant blast crisis cells, IM-resistant acceler-
ated phase cells, IM-resistant chronic phase and CD34þ
progenitors from accelerated and blast crisis patients.
We conclude from these experiments that Jak2 is the main
tyrosine kinase that controls signaling in Bcr–Ablþ cells, as Jak2
appears to use the Bcr–Abl protein as a platform to activate the
Ras and PI-3 kinase pathways by phosphorylating Tyr 177
within the Bcr portion of Bcr–Abl. Jak2 inhibition also strongly
reduced STAT5 tyrosine phosphorylation, possibly because
Jak2 inhibition may reduce functional Bcr–Abl levels. A model
summarizes our current and past ﬁndings on Jak2 functions in
Bcr–Ablþ leukemia (Figure 6f). Importantly, leukemia cells
expressing either IM-resistant forms of Bcr–Abl or having other
forms of drug resistance (such as in blast crisis) undergo
apoptosis on exposure to Jak2 inhibitors
20,21 (Supplementary
Figure 4), suggesting that Jak2 inhibitors have potential for
treatment of drug-resistant CML.
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